LVGN3616

LVGN3616 is a humanized monoclonal antibody that targets programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor. By binding to PD-1, LVGN3616 blocks its interaction with PD-L1, thereby preventing the inhibitory signaling that dampens T-cell activity. This blockade allows for continued or increased production and activation of T-cells, enhancing the immune system's ability to recognize and attack cancer cells. Developed by Lijin Biomedical Technology Shanghai (Lyvgen Biopharma), LVGN3616 is being investigated primarily for use in various solid tumors and cancers where immune evasion via the PD-1/PD-L1 pathway plays a significant role[5][2][4][1].

Other names

Anti-PD1 antibody - Lyvgen BiopharmaAnti-PD-1 antibody - Lyvgen BiopharmaAnti-PD 1 antibody - Lyvgen Biopharma